AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21972424 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg daily for three months (after atorvastatin)
Number of subjects: 40
Study 21972424 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1500 mg daily for three months (after placebo)
Number of subjects: 40
Study 20816118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate/pravastatin combination therapy
Number of subjects: 248
Study 18947338 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 115
Study 18947338 — intervention group
Group type: COMPARATOR
Intervention: Non-penetrating sham acupuncture
Number of subjects: 115
Study 15939064 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (2.5 mg), Vitamin B6 (25 mg), Vitamin B12 (0.5 mg)
Number of subjects: 50
Study 15939064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11826230 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen suspension
Number of subjects: 1879
Study 11826230 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen suspension
Number of subjects: 1879
Study 10411767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with fentanyl 1 microg.kg‐1
Number of subjects: 56
Study 10411767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% with fentanyl 1 microg.kg‐1
Number of subjects: 56
Study 10411767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% without fentanyl
Number of subjects: 56
Study 10411767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% without fentanyl
Number of subjects: 56
Study 8775609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5 micrograms/kg/min for 24 hours)
Number of subjects: 80
Study 8775609 — intervention group
Group type: COMPARATOR
Intervention: Control group (dopamine or amrinone as indicated)
Number of subjects: 80
Study 1955196 — intervention group
Group type: EXPERIMENTAL
Intervention: Troleandomycin (1 g bid over a 10‐day period)
Number of subjects: 6
Study 1955196 — intervention group
Group type: EXPERIMENTAL
Intervention: Josamycin (same doses as T)
Number of subjects: 6
Study 1955196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6762946 — intervention group
Group type: EXPERIMENTAL
Intervention: Culdoscopy
Number of subjects: 395
Study 6762946 — intervention group
Group type: COMPARATOR
Intervention: Minilaparotomy
Number of subjects: 395
Study 30786753 — intervention group
Group type: EXPERIMENTAL
Intervention: Insuring Good Health Intervention (website and video series)
Number of subjects: 243
Study 30786753 — intervention group
Group type: COMPARATOR
Intervention: Lagged-control group
Number of subjects: 243
Study 29118254 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel toothbrush design
Number of subjects: 38
Study 29118254 — intervention group
Group type: COMPARATOR
Intervention: Control reference toothbrush
Number of subjects: 38
Study 29118254 — intervention group
Group type: EXPERIMENTAL
Intervention: Both brushes
Number of subjects: 38
Study 25424602 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil (RO) diet (14-27 g/day) for 13 weeks
Number of subjects: 21
Study 25424602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil (SO) diet (14-27 g/day) for 13 weeks
Number of subjects: 21
Study 23172400 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-oriented (Pa‐O) approach
Number of subjects: 220
Study 23172400 — intervention group
Group type: COMPARATOR
Intervention: Prescription-oriented (Pr‐O) approach
Number of subjects: 220
Study 21483169 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 823
Study 19438913 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (Az)
Number of subjects: 14
Study 19438913 — intervention group
Group type: COMPARATOR
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 14
Study 17530483 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide alone (200 mg/day up to 800 mg/day)
Number of subjects: 28
Study 15005733 — intervention group
Group type: COMPARATOR
Intervention: Sublingual immunotherapy (SLIT) only (n=16)
Number of subjects: 32
Study 15005733 — intervention group
Group type: COMPARATOR
Intervention: Sublingual immunotherapy (SLIT) + one dose of BCG immunization (n=16)
Number of subjects: 32
Study 15005733 — intervention group
Group type: COMPARATOR
Intervention: Control group (inhaled therapy only, PPD-negative asthmatics allergic to HDM, n=5)
Number of subjects: 32
Study 11487597 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAMPS II program
Number of subjects: 173
Study 11487597 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 173
Study 9722121 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose piperacillin (4 g)
Number of subjects: 184
Study 9722121 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-dose piperacillin (3 doses of 2 g)
Number of subjects: 184
Study 9722121 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cephradine and metronidazole (3 doses)
Number of subjects: 184
Study 9722121 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose piperacillin vs. multi-dose piperacillin
Number of subjects: 184
Study 9722121 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups A and C vs. control group D
Number of subjects: 184
Study 9722121 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 184
Study 8057223 — intervention group
Group type: EXPERIMENTAL
Intervention: fortified human milk
Number of subjects: 40
Study 8057223 — intervention group
Group type: COMPARATOR
Intervention: conventional canned sterilized liquid formula
Number of subjects: 40
Study 8057223 — intervention group
Group type: COMPARATOR
Intervention: spray-dried powder formula
Number of subjects: 40
Study 8057223 — intervention group
Group type: COMPARATOR
Intervention: ultra-high-temperature (UHT)-treated liquid formula
Number of subjects: 40
Study 2971692 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg acitretin
Number of subjects: 175
Study 2971692 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg acitretin
Number of subjects: 175
Study 2971692 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg acitretin
Number of subjects: 175
Study 2971692 — intervention group
Group type: COMPARATOR
Intervention: 50 mg etretinate
Number of subjects: 175
Study 2971692 — intervention group
Group type: EXPERIMENTAL
Intervention: All acitretin doses and etretinate
Number of subjects: 175
Study 2971692 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 175
Study 2971692 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin treatment
Number of subjects: 175
Study 2971692 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin and etretinate
Number of subjects: 175
Study 2971692 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks after cessation of treatment
Number of subjects: 175
Study 31854070 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst stimulation
Number of subjects: 100
Study 31854070 — intervention group
Group type: COMPARATOR
Intervention: Tonic stimulation
Number of subjects: 100
Study 31855297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiometabolic risk score (CRS)
Number of subjects: 443
Study 31855297 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 443
Study 31855297 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP)
Number of subjects: 443
Study 31855297 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure (DBP)
Number of subjects: 443
Study 30468526 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable resistance (VR)
Number of subjects: 15
Study 30468526 — intervention group
Group type: COMPARATOR
Intervention: Free-weight resistance (FWR)
Number of subjects: 15
Study 27083774 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal Affect‐Behavior‐Cognition Scale and intensive death‐related questions (Experimental condition)
Number of subjects: 259
Study 27083774 — intervention group
Group type: COMPARATOR
Intervention: Quality of life scale (Control condition)
Number of subjects: 259
Study 27083774 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (Experimental and Control)
Number of subjects: 259
Study 26477278 — intervention group
Group type: EXPERIMENTAL
Intervention: FBZ >10mg/kg once daily for five consecutive days
Number of subjects: 18
Study 26477278 — intervention group
Group type: EXPERIMENTAL
Intervention: moxidectin (MOX) >0.4 mg/kg once
Number of subjects: 18
Study 26477278 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 23444134 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicate calcium phosphate (SiCaP)
Number of subjects: 30
Study 23444134 — intervention group
Group type: EXPERIMENTAL
Intervention: rh-BMP2
Number of subjects: 30
Study 21568746 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium hypoglaucum Hutch (THH) 3 tablets 3 times daily
Number of subjects: 78
Study 21568746 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3 tablets 3 times daily
Number of subjects: 78
Study 21568746 — intervention group
Group type: EXPERIMENTAL
Intervention: THH with cetirizine hydrochloride 10 mg once daily
Number of subjects: 78
Study 21568746 — intervention group
Group type: COMPARATOR
Intervention: Placebo with cetirizine hydrochloride 10 mg once daily
Number of subjects: 78
Study 21568746 — intervention group
Group type: EXPERIMENTAL
Intervention: THH with cetirizine
Number of subjects: 78
Study 21568746 — intervention group
Group type: COMPARATOR
Intervention: Placebo with cetirizine
Number of subjects: 78
Study 18491970 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (900 mg once per day for 8 weeks)
Number of subjects: 26
Study 18491970 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 8 weeks)
Number of subjects: 26
Study 16487695 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T) 4 g/500 mg every 6 h
Number of subjects: 437
Study 16487695 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (IMP) 500 mg/500 mg every 6 h
Number of subjects: 437
Study 14665996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 0
Study 14665996 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 0
Study 11832093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal lymphatic chemotherapy with carboplatin (200 mg) and sandostatin (0.1 mg x 2)
Number of subjects: 0
Study 11832093 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal chemotherapy with carboplatin (200 mg)
Number of subjects: 0
Study 8869860 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 219
Study 8869860 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 219
Study 1630846 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene hydrochloride (DP) 150 mg, twice a day, in a double-blind, randomized, placebo-controlled, crossover trial.
Number of subjects: 25
Study 1630846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1630846 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene hydrochloride (DP)
Number of subjects: 25
Study 6328297 — intervention group
Group type: EXPERIMENTAL
Intervention: oral acyclovir
Number of subjects: 35
Study 6328297 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 35
Study 31974590 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm training group (conventional training + diaphragm strengthening)
Number of subjects: 52
Study 31974590 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional training only)
Number of subjects: 52
Study 30854880 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide (1.5 µg/min)
Number of subjects: 31
Study 30854880 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP38 levels
Number of subjects: 31
Study 30854880 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin gene-related peptide, PACAP38, vasoactive intestinal polypeptide levels during attacks
Number of subjects: 31
Study 27705076 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-task standing
Number of subjects: 265
Study 27705076 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task gait
Number of subjects: 265
Study 27066860 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP-7000 120mg
Number of subjects: 337
Study 27066860 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP-7000 90mg
Number of subjects: 337
Study 27066860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study 24497539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/methotrexate/sirolimus (experimental)
Number of subjects: 146
Study 24497539 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus/methotrexate (standard)
Number of subjects: 146
Study 21985500 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine (10 mg tablet, orally, up to five doses)
Number of subjects: 0
Study 21985500 — intervention group
Group type: COMPARATOR
Intervention: Intravenous labetalol (escalating doses of 20, 40, 80, 80 and 80 mg)
Number of subjects: 0
Study 21985500 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (nifedipine and labetalol)
Number of subjects: 0
Study 20303792 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple grape juice
Number of subjects: 12
Study 20303792 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study 17620675 — intervention group
Group type: EXPERIMENTAL
Intervention: ZoMaxx stent
Number of subjects: 90
Study 17620675 — intervention group
Group type: COMPARATOR
Intervention: TriMaxx stent
Number of subjects: 90
Study 15690201 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-cm² polypropylene mesh (subgroup Ib)
Number of subjects: 36
Study 15690201 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-cm² polypropylene mesh (subgroup IIb)
Number of subjects: 36
Study 15690201 — intervention group
Group type: COMPARATOR
Intervention: Conventional repair (subgroup Ia)
Number of subjects: 36
Study 15690201 — intervention group
Group type: COMPARATOR
Intervention: Conventional repair (subgroup IIa)
Number of subjects: 36
Study 11755749 — intervention group
Group type: EXPERIMENTAL
Intervention: Enantioselective high-performance liquid chromatographic (HPLC) method for chlorpheniramine and metabolites
Number of subjects: 0
Study 9521367 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipstick urinalysis for UTI or hematuria
Number of subjects: 166
Study 9521367 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipstick urinalysis for hematuria
Number of subjects: 166
Study 9521367 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall management based on dipstick urinalysis
Number of subjects: 166
Study 8024127 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 minimum alveolar concentration isoflurane
Number of subjects: 8
Study 8024127 — intervention group
Group type: COMPARATOR
Intervention: Control (carrier gas)
Number of subjects: 8
Study 2478426 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch (50 g) pudding meal (400 ml) with water (200 ml)
Number of subjects: 14
Study 2478426 — intervention group
Group type: COMPARATOR
Intervention: Placebo with water (200 ml)
Number of subjects: 14
Study 2478426 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylase inhibitor (5 or 10 g) with water and starch
Number of subjects: 14
Study 2478426 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylase inhibitor (4 g) with water and starch
Number of subjects: 14
Study 2478426 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylase inhibitor (5 or 10 g)
Number of subjects: 14
Study 796954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen
Number of subjects: 0
Study 796954 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (soluble form of acetylsalicylic acid)
Number of subjects: 0
Study 31499228 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication & Coping intervention (telephone and Facebook-delivered)
Number of subjects: 0
Study 31499228 — intervention group
Group type: COMPARATOR
Intervention: Diabetes education control condition
Number of subjects: 0
Study 28596023 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (OI; 8 g/day)
Number of subjects: 42
Study 28596023 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo (isocaloric dose)
Number of subjects: 42
Study 25939604 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating LCN2 levels above the median (76.6 ng/mL)
Number of subjects: 1009
Study 25939604 — intervention group
Group type: EXPERIMENTAL
Intervention: Per standard deviation increase in LCN2
Number of subjects: 1009
Study 23863583 — intervention group
Group type: EXPERIMENTAL
Intervention: Water group - patients drank 500 mL water after dinner on the evening before endoscopy, and 350 mL water before the examination.
Number of subjects: 0
Study 23863583 — intervention group
Group type: COMPARATOR
Intervention: Control group - patients drank nothing after dinner and nothing on the day of endoscopy.
Number of subjects: 0
Study 23863583 — intervention group
Group type: EXPERIMENTAL
Intervention: Water group - specifically in patients with distal gastrectomy.
Number of subjects: 0
Study 23863583 — intervention group
Group type: EXPERIMENTAL
Intervention: Water group - in patients who underwent proximal gastrectomy or pylorus-preserving gastrectomy.
Number of subjects: 0
Study 21954526 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg morphium hydrochloride (MCh)
Number of subjects: 40
Study 21954526 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg morphium hydrochloride (MCh)
Number of subjects: 40
Study 19505307 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone therapy (HT)
Number of subjects: 1778
Study 19505307 — intervention group
Group type: COMPARATOR
Intervention: Non-hormone therapy (non-HT)
Number of subjects: 1778
Study 17014006 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 10 mg/kg
Number of subjects: 0
Study 17014006 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 2 mg/kg
Number of subjects: 0
Study 17014006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12756979 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated iron(II) fumarate sprinkles
Number of subjects: 437
Study 12756979 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated iron(II) fumarate sprinkles with vitamin A
Number of subjects: 437
Study 12756979 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron(II) sulfate drops
Number of subjects: 437
Study 12756979 — intervention group
Group type: COMPARATOR
Intervention: Placebo sprinkles
Number of subjects: 437
Study 12756979 — intervention group
Group type: COMPARATOR
Intervention: No intervention (12 months post-supplementation)
Number of subjects: 437
Study 11317165 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 13000
Study 9316951 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 715
Study 9316951 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous meperidine analgesia
Number of subjects: 715
Study 8444328 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 64
Study 8444328 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 64
Study 8444328 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 64
Study 3742833 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg daily in 5 ml corn-oil)
Number of subjects: 12
Study 3742833 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle only)
Number of subjects: 12
Study 30025470 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 0
Study 30025470 — intervention group
Group type: COMPARATOR
Intervention: Air (sham)
Number of subjects: 0
Study 27595996 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation oncology teaching (lectures, seminars, practices)
Number of subjects: 40
Study 27028316 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg spray
Number of subjects: 505
Study 27028316 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 505
Study 25064291 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic dietary recording system (EG)
Number of subjects: 60
Study 25064291 — intervention group
Group type: EXPERIMENTAL
Intervention: Food diary (FD)
Number of subjects: 60
Study 25064291 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study 21881905 — intervention group
Group type: EXPERIMENTAL
Intervention: Light deprivation (LD)
Number of subjects: 2
Study 21881905 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental light exposure (EL)
Number of subjects: 2
Study 21881905 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (CS)
Number of subjects: 2
Study 21881905 — intervention group
Group type: EXPERIMENTAL
Intervention: Short‐interval intracortical inhibition and ratios between motor‐evoked potential amplitudes and supramaximal M responses
Number of subjects: 2
Study 21881905 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term variation of motor thresholds (MTs)
Number of subjects: 2
Study 19066295 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (0.5 mg every day) plus standardized diet and exercise program
Number of subjects: 24
Study 19066295 — intervention group
Group type: COMPARATOR
Intervention: Standardized diet and exercise program
Number of subjects: 24
Study 17166305 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) at the globus pallidus internus (GPi)
Number of subjects: 42
Study 17166305 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) at the subthalamic nucleus (STN)
Number of subjects: 42
Study 17166305 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided deep brain stimulation (DBS)
Number of subjects: 42
Study 17166305 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral treatment
Number of subjects: 42
Study 17166305 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral treatment
Number of subjects: 42
Study 16327304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (group I, n = 30)
Number of subjects: 60
Study 16327304 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (group II, n = 30)
Number of subjects: 60